𝔖 Bobbio Scriptorium

✦ LIBER ✦

Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods

✍ Scribed by Bruce J. Kinon; Dilip V. Jeste; Sara Kollack-Walker; Virginia Stauffer; Hong Liu-Seifert

Book ID: 116840357
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 753 KB
Volume: 28
Category: Article
ISSN: 0278-5846
DOI: 10.1016/j.pnpbp.2004.05.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clinical effectiveness of the Kampo medi

Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: A 16-week open trial

✍ JUNG GOO LEE; BAE SUB SHIN; YU CHEOL LEE; SUNG WOO PARK; YOUNG HOON KIM 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB

Efficacy and Tolerability of Fimasartan,

Efficacy and Tolerability of Fimasartan, a New Angiotensin Receptor Blocker, Compared With Losartan (50/100 mg): A 12-Week, Phase III, Multicenter, Prospective, Randomized, Double-Blind, Parallel-Group, Dose Escalation Clinical Trial With an Optional 12-Week Extension Phase in Adult Korean Patients With Mild-to-Moderate Hypertension

✍ Sang Eun Lee; Yong-Jin Kim; Hae-Young Lee; Han-Mo Yang; Chang-Gyu Park; Jae-Joon 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 806 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB